The affected employees are mainly part of the company's research and development (R&D) department.
The move is in line with the firm's strategic plan. Zeltia has a 63.67% stake in Noscira.
In September 2011, Noscira unveiled a capital increase of up to EUR4m (USD5.16m) seeking to finance studies of Alzheimer's disease.
(EUR1 = USD1.288)
Samsung Biologics honoured at 2026 CDMO Leadership Awards
Frost & Sullivan names Abzena a market-leading ADC CDMO
Vulcan Two signs five-year ERP licence agreement to support ePharmacy expansion
SportsMed Physical Therapy named Physical Therapy Company of the Year
Ensorcell adds new senior leadership team members
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme